基斯变异:阿尔茨海默病的关键因素
Kun Li1, Xiaolin Qiu2, Qiqi Yang2
1Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China.
Mechanisms of ageing and development
|September 4, 2025
概括
在阿尔茨海默病 (AD) 病理学中,像乙化,克罗化和乳化这样的基因组修饰是关键. 针对这些改变为阿尔茨海默病治疗提供了一个有前途的新途径.
科学领域:
- 神经科学
- 表观遗传学
- 生物化学
背景情况:
- 阿尔茨海默病是老年人认知能力下降的主要原因.
- 目前阿尔茨海默病的治疗方法不足以阻止疾病的进展.
- 迫切需要新的AD生物标志物和治疗点.
研究的目的:
- 审查基因素修饰在阿尔茨海默病病变中的作用.
- 探讨基因组修饰和阿尔茨海默病的特征之间的关联.
- 评估基因组修饰酶作为阿尔茨海默病的潜在治疗点.
主要方法:
- 关于基因素修饰和AD现有研究的文献综述.
- 分析基因素修饰和粉样β积累之间的联系.
- 检查 histone 修饰和 Tau 蛋白质过化之间的联系.
主要成果:
- 基因组乙化,克罗化和乳化与阿尔茨海默病理有关.
- 这些变化与粉样质斑块和团相关.
- 基斯变化与神经炎症和突触功能障碍有关.
结论:
- 在阿尔茨海默病的发病过程中,基因组的修饰起着核心作用.
- 基因组修饰酶是阿尔茨海默病治疗的有希望的治疗点.
- 对表观遗传机制的进一步研究可以解锁新的阿尔茨海默病疗法.
相关概念视频
Spreading of Chromatin Modifications
8.5K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.5K
Histone Modification
13.8K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.8K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Histone Variants at the Centromere
4.5K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.5K
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Chromatin Modification in iPS Cells
1.9K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.9K


